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Abstract 
Purpose: Ovarian cancer is a leading cause of death among gynaecological malignancies. 
Transforming growth factor-beta 1 (TGF-β1) and interleukin-10 (IL-10) are cytokines in the tumour 
microenvironment and may play critical roles in immune suppression. This study highlights these roles 
and immunosuppressive functions in epithelial ovarian cancer (EOC).  
Methods: TGF-β1 and IL-10 expression was compared in malignant, benign, and borderline cancerous 
tissues and tumour-free tissue by immunohistochemistry. Relationships among the levels of these 
cytokines, correlation of expression level with EOC prognosis, and cytokine involvement in 
immunosuppression were investigated.      
Results: Immunohistochemical analysis of TGF-β1 and IL-10 in epithelial cells showed the presence of 
epithelial, borderline, and benign ovarian tumour growth, and normal ovarian growth. TGF-β1 (P = 
0.121), residual tumour after surgery (P = 0.231) and standard chemotherapy (P = 0.121) were 
prognostic factors for EOC. There were no significant differences in clinicopathologic factors between 
specimens expressing TGF-β1 at low and high levels, indicating that TGF-β1 is an independent factor in 
EOC diagnosis. Higher concentrations of TGF-β1 (1754.690 ± 3416.487 pg/ml) and IL-10 (2731.7101 ± 
6.1613 pg/ml) were observed in A2780-conditioned than in control medium.  
Conclusion: TGF-β1 and IL-10 play pivotal roles in EOC and can lead to immune evasion. Targeting 
these cytokines for tumour treatment, specifically at early stages, may prevent tumour progression.   
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Ovarian cancer is a leading cause of death 
among gynaecological malignancies. Several 
surveys have been conducted to determine the 
causative factors in the development of 
malignant ovarian epithelial cells. Epithelial 
ovarian cancer (EOC) accounts for about 85–90 
% of all ovarian cancers and is the leading cause 
of gynaecological malignancies in North America 
and worldwide. Despite all of the recent 
advances in treatment, the 5-year survival of 
patients with advanced stage disease remains 
less than 40 % [1,2]. 
 
Ovarian cancer cells have the ability to create an 
immunosuppressive environment around the 
tumour and to escape immune monitoring. 
Ovarian cancer spreads intra-abdominally and is 
restricted primarily to the peritoneal cavity, where 
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most immunosuppressive activity takes place, 
modulated by the tumour microenvironment. 
Hence, this microenvironment modulates 
invasion, progression, and metastasis of ovarian 
cancer. Taking place in the tumour 
microenvironment are cell-cell signalling and 
cellular-extracellular component interactions, 
which regulate inter/intracellular processes, such 
as proliferation, differentiation, and programmed 
cell death, as well as secretion and activation of 
soluble cytokines [3]. Despite the availability of 
diverse treatment strategies and accessibility to 
new cytotoxic agents, survival rates have not 
substantially improved [4]. Therefore, new 
treatment options targeting cancer cells and, in 
particular, putative cancer stem cells are required 
as first-line therapies and/or initial treatment of 
recurrent ovarian cancer. 
 
The transforming growth factor β (TGF-β) 
superfamily signalling pathways are ubiquitous 
and essential regulators of cellular processes, 
such as proliferation, differentiation and 
migration. TGF-β signalling pathways also play 
essential roles in physiological processes, 
including embryonic growth, angiogenesis, and 
wound healing. Appropriate regulation of these 
pathways is needed, because either a deficiency 
or an excess of a specific TGF-β superfamily 
ligand may result in pathology [5]. 
 
TGF-β is a cytokine with pleiotropic functions in 
hematopoiesis, angiogenesis, cell proliferation, 
differentiation, migration, and apoptosis [6]. TGF-
β also inhibits T-cell functions by blocking both 
proliferation and specialization. Despite the 
existence of tumour-specific antigens and the 
presence of tumour-specific immune cells, the 
majority of tumours manage to avoid immune-
mediated destruction. Several mechanisms have 
been proposed for tumour immune evasion. One 
such mechanism is believed to be mediated by 
TGF-β1, an immunosuppressive cytokine found 
at the site of most tumours [8,9], and suggests 
that TGF-β uses multiple mechanisms to ensure 
immunological tolerance, which is a critical 
feature of autoimmune and inflammatory 
disorders. TGF-β1 is an essential regulator of 
immune responses, suppressing B-cell 
proliferation and synthesis of immunoglobulin 
(IgG and IgM), and blocking proliferation of 
thymocytes, T-lymphocytes, and large granular 
lymphocytes [10-12]. Interleukin-10 (IL-10) is 
another immune regulatory cytokine that targets 
T cells, antigen-presenting cells, and related 
immune cells. Immunosuppressive roles of IL-10 
in the tumour microenvironment have also been 
reported; however, some studies suggest 
immunostimulatory functions of IL-10, and the 
role of IL-10 in ovarian cells is controversial.   
 
In the present work, expression levels of TGF-β1 
and IL-10 were determined in ovarian tissues, 
including malignant, borderline, and benign 
tumour and normal tissues. Furthermore, 
correlation between expression levels of these 
cytokines and clinicopathologic features, and 
potential involvement of these cytokines in the 
immunosuppressive microenvironment of ovarian 






One hundred and twenty-five patients (20–60 
years of age) with histologically confirmed 
primary ovarian tumours were classified in the 
histological groups malignant (n = 60), borderline 
(n = 15), and benign (n = 50). These specimens 
were obtained from patients undergoing primary 
debulking surgery at the Oncology Cancer 
Center Southern Medical University, Guangzhou, 
China. The malignant group included serous 
adenocarcinoma (n = 48), malignant mixed 
mesodermal tumours (n = 5), mucinous 
adenocarcinoma (n = 6), clear-cell carcinomas (n 
= 5), non-Brenner type transitional cell carcinoma 
(n = 3), and malignant Brenner tumour (n = 2). 
The borderline group consisted of serous (n = 6) 
and mucinous (n = 10). The benign group 
included serous cystadenoma (n = 7), mucinous 
cystadenoma (n = 9), endometrial cyst (n = 3), 
simple cyst (n = 5), fibroma (n = 4), cystic follicle 
(n = 1), and serous cysts (n = 1). All experiments 
were performed following the protocols 
recommended by the Research Ethics 
Committees of the Department of Gynecologic, 
Oncology Cancer Center Southern Medical 
University, Guangzhou, China; Department of 
Gynecologic, Guangzhou Women and Children's 
Medical Center, Guangzhou Medical College, 
Guangzhou, China; Department of Gynecology 
and Obstetrics, Guangdong Provincial Corps 
Hospital, Chinese People Armed Forces, 
Guangzhou, China; Guangzhou Women and 
Children's Medical Center, Affiliate of Guangzhou 




Ovarian tumour specimens free of necrotic tissue 
were identified from primary and metastatic 
tumours by a pathologist. Tissues were 
embedded in PolyFreeze tissue freezing medium 
(Polysciences, Warrington, PA, USA), snap-
frozen in liquid nitrogen, and stored at -80 °C. 
Use of frozen, rather than paraffin-embedded, 
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specimens has the advantage that unmasking of 
denatured antigens is not needed. Serial 5-μm 
sections of the tumours were excised, mounted 
on Superfrost Plus microscope slides, and air-
dried. Staining was carried out as previously 
described [13]. Briefly, the mounted sections 
were fixed in acetone for 5 min and rapidly 
transferred to phosphate-buffered saline (PBS). 
The slides were washed with 0.3 % H2O2 in 
methanol for 10 min. After a short rinse, the 
slides were immersed in citrate buffer and heated 
at 100 °C in a water bath for 15–20 min. Slides 
were cooled to room temperature, rinsed, and 
normal goat serum was applied to the sections 
for 20 min to block nonspecific binding. Sections 
were then incubated overnight at 4 °C with 
specific antibodies directed against TGF-β1 and 
IL-10 (Biolegend, San Diego, CA, US). 
Localization of antigen-antibody complexes was 
performed with the streptavidin-peroxidase 
technique using SP® Kits (Zymed, South San 
Francisco, CA, USA). Finally, sections were 
counterstained with Mayer’s hematoxylin. 
 
Cells and culture  
 
A2780 human ovarian cancer cells were 
obtained from the American Type Culture 
Collection (Manassas, VA, USA), cultured in 
RPMI 1640 (Gibco-BRL/Life Technologies, 
Grand Island, NY, USA) containing 15 % calf 
serum (Gibco-BRL/Life Technologies), 100 U/ml 
penicillin, and 100 mg/ml streptomycin, and 
maintained at 37 °C in a humidified atmosphere 
of 5 % CO2. When cultures were 85–90 % 
confluent, the medium was replaced with serum-
free RPMI 1640. The conditioned medium was 
decanted and used in further experiments. 
Concentrations of TGF-β1 and IL-10 in the 
conditioned medium were determined using a 
human enzyme-linked immunosorbent assay 
(ELISA) kit (R&D Systems, Minneapolis, MN, 
USA). Concentrated serum-free RPMI 1640 
served as negative control. 
 
Peripheral blood mononuclear cells (PBMCs) 
from healthy adult donors who had provided 
consent were separated by Ficoll-Hypaque (GE 
Healthcare, Little Chalfont, UK) density gradient 
centrifugation. The plastic-adherence method 
was applied to separate monocytes from 
lymphocytes. Lymphocytes and monocytes were 
cultured in serum-free AIM-V medium, containing 
1,000 U/mL recombinant human (Rh) 
granulocyte-macrophage colony stimulating 
factor (GM-CSF) and 1,000 U/mL Rh IL-4 
(Peprotech) to generate immature dendritic cells, 
at 37 °C in a humidified atmosphere of 5 % CO2 
for 6 days. Then conditioned A2780 cell medium 
or negative control medium was added to the 
culture medium of lymphocytes and immature 
dendritic cells, and cells were incubated for 
another 3 days. Human TGF-β1 and IL-10 were 
added to cultures of lymphocyte and immature 
DCs separately. 
 
Flow cytometric analysis 
 
Flow cytometric analysis was carried out using 
the method described by Liu et al [3]. Briefly, 
dendritic cells were labeled extracellularly with 
fluorescein isothiocyanate (FITC)-conjugated 
anti-human CD83 and phycoerythrin (PE)-
conjugated anti-human CD1a (BD Biosciences, 
San Jose, CA, USA). The cells were stained 
intracellularly with allophycocyanin (APC)-
conjugated anti-human FoxP3 (eBioscience, San 
Diego, CA, USA). FITC-conjugated normal 
mouse IgG1, PE-conjugated normal mouse 
IgG2, and APC-conjugated normal mouse IgG2 
(BD Biosciences) were used as isotype controls. 
At least 50,000 cells/sample were processed with 
an LSR II cell analyser (BD Biosciences), and the 





Kruskal-Wallis test was used to measure TGF-β1 
and IL-10 expression in ovarian tissues. The 
probability of survival was estimated by Kaplan-
Meier and log rank test. Predictive factors were 
defined by multifactor logistic regression. P < 
0.05 was considered to be statistically significant. 
All statistical analyses were performed using 
GraphPad Prism 6.0 (GraphPad Software, La 




TGF-β1 and IL-10 expression in EOC patients 
 
The average photosensitive density of TGF-β1 is 
0.210–0.400; therefore, intervals of 0.010 from 
0.163 to 0.440 were calculated and analysed by 
Kaplan-Meier and log rank tests to define the cut-
off level. The greatest difference occurred at A = 
0.351 (p = 0.013). The survival time of the TGF-
β1low group (A < 0.325) was 76.90 ± 8.14 
months, whereas survival of the TGF-β1 high 
was 65.0 ± 7.98 months. The difference between 
these groups approached statistical significance 
(p = 0.048). Immunohistochemical analysis of 
TGF-β1 and IL-10 was carried out in normal 
ovarian tissue samples and in samples of benign 
and malignant ovarian tumours (Figure 1). 
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Figure 1: Immunohistochemical staining of TGF-β1 and IL-10 in the indicated types of ovarian tissue specimens 
(×200) 
 
TGF-β1 was not expressed in normal ovarian 
tissue; it was weakly expressed in ovarian 
mucinous cystadenoma and ovarian borderline 
serous and markedly expressed in serous 
ovarian cancer. IL-10 was not expressed in 
normal ovarian tissue; it was weakly expressed 
in ovarian mucinous cystadenoma, moderately 
expressed in borderline serous cystadenoma, 
and significantly expressed in ovarian carcinoma. 
 
IL-10 expression was observed in 45 of 79 
specimens (56.96 %). The survival time of the 
negative group was 91.728 ± 7217 months, 
whereas that of the positive group (45/79) was 
60.411 ± 9.512 months (p = 0.548) (Figure 2A 
and B). 
 
Clinical and pathological profiles and patient 
prognosis 
 
Clinicopathological factors including patient age, 
histological grade and FIGO stage of the tumour, 
residual tumour after surgery, lymphatic 
metastasis, and standard chemotherapy (data 
not shown) were examined. The results showed 
that TGF-β1, residual tumour after surgery, and 
standard chemotherapy are prognostic factors for 
EOC (p = 0.121, 0.231, and 0.121, respectively). 
Correlation of TGF-β1 expression with other 
clinicopathological factors was also recorded 
(data not shown). No substantial differences 
were observed in clinicopathological factors of 
TGF-β1Low and TGF-β1High, which implies that 
TGF-β1 is an independent factor that does not 
influence the prognosis of EOCs.  
 
TGF-β1 and IL-10 expression levels in culture 
supernatants 
 
High levels of TGF-β1 (1754.690 ± 3416.487 
pg/ml) and IL-10 (2731.7101 ± 6.1613 pg/ml) 
were detected in culture medium conditioned by 
A2780 cells compared to unconditioned negative 
control medium. 
 
Ovarian cancer immunosuppressive 
responses  
 
Different concentrations of A2780 conditioned 
medium were added to lymphocyte and 
immature dendritic cell (DC) cultures. When the 
concentration of TGF-β1 in the conditioned 
medium was high (final concentration >300 pg/ml 
in CFHigh), the proportion of immature CD1a+ 
immature DCs increased significantly, whereas 
the proportion of CD83+ mature DCs decreased. 
These responses were not induced by treatment 
of cells with the same concentration of TGF-β1 in 
the absence of A2780 conditioned medium. 
When inadequate supernatant (CFLow+TGF-β1 or 
CFLow+IL-10) was incubated with lymphocytes 
and DCs, DC maturation was impaired. 
Furthermore, ELISA was performed to determine 
IL-10 concentration in DC cultures and showed 
that DCs cultured in CFHigh secreted higher levels 
of IL-10 than those cultured in CFLow. It was also 
observed that the presence of enough TGF-β1 in 
supernatant interfered with dendritic cell 
maturation (Figure 2C & D). 
 
Flow cytometry data 
 
Various amounts of A2780 conditioned medium 
were added to DC and lymphocyte cultures, and 
maturation and regulation of T-lymphocytes were 
analysed using flow cytometry (Figure 3). When 
cells were treated with CFHigh (final TGF-β1 
concentration >800 pg/ml), the number of mature 
CD83+ DCs decreased, and CD1a expression 
significantly increased. 
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Figure 2: (A). Survival curve for 100 epithelial ovarian cancer (EOC) patients with low or high level of TGF-β1 
expression. (B). Survival curve of 100 EOC patients with IL-10 nonexpression. (C) Immunosuppressive response 
of CD83+ and CD1a+ dendritic cells (DCs) to the indicated treatments (**p < 0.01, *p < 0.05).(D). Concentration of 
IL-10 in DC culture supernatants (**p < 0.01). Cum, cumulative 
 
 
Figure 3: Flow cytometric analysis of immunosuppressive response. Dendritic cells were gated in R1, and CD83+ 




EOC is the most lethal disease among 
gynaecological malignancies. It is the fourth 
leading cause of malignant neoplastic disease-
associated deaths in women in the United States 
and the fifth most common malignancy in adult 
females in developed countries [14]. TGF-β1 is a 
multifunctional growth factor that has profound 
regulatory effects on many developmental and 
physiological processes. Hurteau et al [17] 
identified TGF-β in most ovarian tumour tissue 
samples examined, whether benign or malignant. 
Some published work has also reported the 
contradictory observation that not all ovarian 
cancers express TGF-β. 
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In the majority of patients, risk of EOC is linked to 
incessant ovulation, i.e., chronically repeated 
formation of stromal epithelial clefts and inclusion 
cysts after ovulation [19]. Members of the TGF-β 
family have shown distinct cell-specific patterns 
of expression at various stages of development, 
including in the three primary embryonic germ 
layers [20]. The TGF-β family is an important 
family of cytokines that may promote tumour 
development in vivo through several 
mechanisms, including interference with 
antitumour T-cell immune responses, alteration 
of factors in the stroma and extracellular matrix, 
and promotion of angiogenesis. TGF-β isotypes 
have been found in malignant tumour and normal 
ovarian tissues [21]. EOC is notoriously lethal 
and little is known about its pathogenesis [22]. 
 
In the present study, roles played by TGF-β 1 
and IL-10 in the initiation and spread of EOC 
were determined. Samples of normal and tumour 
tissue were collected from randomly selected 
ovarian cancer patients, and relative levels of 
TGF-β1 and IL-10 expression were determined 
using immunohistochemical staining of tissue 
sections. TGF-β1 and IL-10 expression were 
significantly higher in cancerous tissues than in 
normal tissues. These results confirmed that 
these cytokines are frequently overexpressed in 
EOC. Some studies had suggested that 
expression of these cytokines is correlated; e.g., 
TGF-β1 was simultaneously overexpressed with 
IL-10 and vascular endothelial growth factor 
(VEGF) in oesophageal squamous cell 
carcinoma, and IL-10 expression was induced in 
melanoma. In contrast to those findings, TGF-β1 
and IL-10 expression were not correlated in the 
present study.  Statistical analysis revealed that 
TGF-β1 expression, residual tumour, and 
chemotherapy were important prognostic factors 
for EOC. Moreover, no correlation was observed 
between TGF-β1 expression, FIGO stage, 
patient age, residual tumour, histological grade, 
lymphatic metastasis, or standard chemotherapy. 
Therefore, TGF-β1 may be considered an 
independent prognostic factor for EOC.  
 
TGF-β1 and IL-10 are important cytokines that 
have been reported to induce 
immunosuppression, and overexpression of the 
cytokines suggests their possible involvement in 
immune evasion by EOC. DCs are considered 
the most important antigen-presenting cells. 
Based on the role of DCs in immunosuppressive 
responses, immunosuppressive functions of IL-
10 and TGF-β1 were probed. In vitro 
experiments revealed that TGF-β1 interfered with 
DC maturation, and immature DCs secreted 
increased levels of IL-10. Although TGF-β1 and 
IL-10 play important roles in immunosuppressive 
responses, the cytokines alone were not able to 
elicit these responses and, in our study, 
treatment of cells with A2780 conditioned 





This study confirmed that overexpression of 
TGF-β1 and IL-10 performs a significant function 
in EOC and contributes to frequent immune 
evasion events. Targeting these cytokines for 
tumour treatment, particularly in the early stages 
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